Physician profile
Anthony Chavez
NPI 1215582176
$9,283.46
in general payments reported to CMS, 2019-2025
20 companies · $3,122 in 2025
The $3,122 reported for 2025 was more than what 98% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $94.41 · 2020: $363 · 2021: $809 · 2022: $1,698 · 2023: $1,205 · 2024: $1,993 · 2025: $3,122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,153 · Gift: $166.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,152.74 |
| Gift | $166.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $2,791.42 | 2020-2025 | Acuvue |
| Bausch & Lomb Americas INC. | $2,554.82 | 2022-2025 | Infuse, Biotrue, Miebo |
| Alcon Vision LLC | $1,066.82 | 2022-2025 | Tryptyr, Precision7, Rocklatan |
| Coopervision INC. | $709.72 | 2021-2025 | Misight Contact Lens, Myday Contact Lens, Clariti Contact Lens |
| Dompe US, INC. | $387.64 | 2023-2025 | Oxervate |
| Glaukos Corporation | $300.91 | 2020-2025 | Idosetr, Istent Infinite |
| Rxsight INC | $283.22 | 2024-2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Sun Pharmaceutical Industries INC. | $267.29 | 2019-2024 | Cequa |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $168.12 | 2020-2021 | |
| Visionary Optics LLC | $166.25 | 2024 | |
| Amgen INC. | $136.91 | 2025 | Tepezza |
| Oyster Point Pharma, INC. | $124.77 | 2022-2025 | Tyrvaya, Ryzumvi |
| Eyevance Pharmaceuticals LLC | $122.84 | 2021 | |
| Abbvie INC. | $76.34 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $38.89 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $23.15 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $21.04 | 2024 | Xdemvy |
| Aerie Pharmaceuticals, INC. | $15.93 | 2021 | |
| Thea Pharma INC. | $14.32 | 2022 | |
| Biotissue Holdings INC. | $13.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Chavez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.